SAGE Therapeutics (SAGE) Misses Q3 EPS by 36c, Reports $1.8B of Cash on Hand

SAGE Therapeutics (NASDAQ: SAGE) reported Q3 EPS of ($2.21), $0.36 worse than the analyst estimate of ($1.85). Revenue for the quarter came in at $1.44 million versus the consensus estimate of $1.96 million.

For earnings history and earnings-related data on SAGE Therapeutics (SAGE) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Carnival Corp. (CCL) Tops Q2 EPS by 8c, Beats on Revenue; Offers Guidance
• JPMorgan Downgrades Tata Technologies (TATATECH:IN) to Underweight